U.S. proposes Medicare coverage for CAR-T cancer therapies
The U.S. Centers for Medicare & Medicaid Services proposed Medicare coverage of approved CAR-T cell therapies that use the patient’s immune system to fight cancer.
Takeda’s fiscal third-quarter profit rises 28 percent on strong sales of main drugs
Takeda Pharmaceutical Co. Ltd. posted a 27.9 percent rise in operating profit for the October-December 2018 period, supported by strong sales of the company’s drugs for bowel disease and multiple myeloma.
FDA Approves Imbruvica for 10th Time
FDA approved Imbruvica combined with Gazyva for adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.
Imbruvica fails to meet pancreatic cancer study goal
AbbVie Inc.’s blockbuster cancer treatment Imbruvica in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer.
BioNTech teams up with Sanofi to target solid tumors
Germany-based BioNTech extended a three-year-old collaboration with Sanofi as the companies look to co-develop the first cancer immunotherapy candidate for solid tumors.
Investing Into R&D Pays off for Some of Biotech’s Biggest Companies
PwC’s annual R&D spending report showcases companies that stand out in the field of biotechnology.
Genentech Cutting More Jobs in Bay Area
South San Francisco-based Genentech filed with the State of California, indicating that the Roche company planned to cut 83 jobs.
J&J-AbbVie cancer drug Imbruvica succeeds in late-stage trial
Johnson and Johnson said a combination therapy containing the company’s blockbuster cancer drug Imbruvica significantly improved survival in blood cancer patients, compared with drugs currently used as the standard of care.
Johnson & Johnson’s multiple myeloma drug reduces risk of death in late-stage study
Johnson & Johnson’s blockbuster blood cancer drug Darzalex significantly reduced the risk of disease progression or death in patients who have not been previously treated for multiple myeloma, late-stage study data showed.
High-cost Gilead cell therapy proves durable for some lymphoma patients
Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc.’s Yescarta were still responding to the cell therapy after at least two years of follow-up.
Ad Right Top
MedAdNews
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.
February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!